Skip to content
Review Open access

Outcomes of inpatient chemotherapy following multidisciplinary review in patients with solid tumors at an academic cancer center.

Oct 2026 · JCO Oncology Practice · 0 citations

TL;DR

Nearly one-third of patients undergoing multidisciplinary review for inpatient chemotherapy died within 30 days of request, highlighting the medical complexity of this population of patients.

Abstract

603 Background: Inpatient chemotherapy is frequently administered to hospitalized patients with advanced solid tumor malignancies and has been associated with poor outcomes and high resource utilization. A quality improvement intervention established mandatory multidisciplinary review for all inpatient solid tumor chemotherapy requests at our institution. We sought to characterize the clinical outcomes of patients undergoing evaluation after implementation of this review process. Methods: We performed a retrospective review of inpatient chemotherapy requests for patients with solid tumors submitted at a tertiary academic medical center between April 2024 and January 2026. Demographic, clinical, laboratory, and treatment-related data were collected, including infection and functional status, treatment delivery (administered vs. not administered), discharge disposition, mortality, and hospice utilization. Infection status was characterized by objective imaging findings or positive microbiological culture data at the time of chemotherapy request. Functional status was abstracted from physical therapy documentation and characterized as independent ambulation, minimal/moderate assistance, maximal assistance, or not assessed/declined. Descriptive statistics were used to summarize patient characteristics and outcomes. The primary outcome was 30-day mortality from the date of inpatient chemotherapy request. Results: Out of 144 unique inpatient chemotherapy requests for 133 patients, 96 (66.7%) were approved, while 46 (32.4%) were denied. Among approved requests, chemotherapy was delivered during hospitalization in 81 patients (82.7%) and not delivered in 17 (17.3%). Thirty-day mortality for the overall cohort was 31.2% (44/141). Patients with approved requests had substantially lower 30-day mortality than those with denied requests (23/96 [24.0%] vs. 21/45 [46.7%]). Active infection was associated with 30-day mortality of 48.5% (16/33), elevated bilirubin >1.5x the upper limit of normal with 56.3% (9/16), and maximal assistance with ambulation with 73.3% (11/15). Conclusions: Nearly one-third of patients undergoing multidisciplinary review for inpatient chemotherapy died within 30 days of request, highlighting the medical complexity of this population. Patients whose requests were denied experienced substantially higher short-term mortality than approved patients, suggesting the review process identifies individuals at particularly high risk for poor outcomes. Active infection, hyperbilirubinemia, and severe functional impairment were associated with especially high 30-day mortality and may represent objective factors for consideration in future refinement of inpatient chemotherapy review criteria.

Read PDF

Similar papers

Open access Oct 2026

Clinical drivers and early outcomes of inpatient chemotherapy in gastrointestinal oncology: A retrospective cohort study.

596 Background: Inpatient chemotherapy for gastrointestinal (GI) malignancies is used selectively for patients with urgent clinical needs or barriers to outpatient treatment, but indications, outcomes, and predictors of early mortality remain poorly defined. We characterized the clinical drivers and short-term...

A. Barabrah, M. Overman, Lian-Chun Xiao et al. · 0 citations
Open access Oct 2026

Utility (or futility) of inpatient chemotherapy in patients with advanced solid organ cancers near end of life (FOCUS-EOL).

289 Background: Chemotherapy near the end of life carries limited clinical benefit. We evaluated outcomes of patients with solid organ malignancies who received inpatient cytotoxic chemotherapy at a tertiary cancer center. Methods: We performed a retrospective study of adults with solid organ malignancies who...

Adeel Arshad, P. Bhateja, Alyssa Antonini et al. · 0 citations
Open access Oct 2026

Functional status to predict acute care utilization among patients receiving systemic anticancer therapy in a QMENTUM diamond cancer center: A real-world cohort study.

The findings support the incorporation of PS assessment into routine oncology practice to identify patients who may benefit from targeted supportive care strategies and closer monitoring, supporting proactive care delivery within high-quality oncology programs.

Victória Santos Marques Pereira, Carolline Damas de Andrade Oliveira, Thays Andreza So Vale da Fonseca et al. · 0 citations
Open access Oct 2026

Delays in oncologic care for newly diagnosed thoracic malignancies: A quality improvement analysis at a single institution.

551 Background: Patients with newly diagnosed thoracic malignancies frequently experience delays in diagnosis and treatment initiation, particularly during transitions from inpatient to outpatient oncologic care. Geographic barriers and limited access to specialty services may contribute to treatment delays. We...

Aariez Khalid, Anita Mazloom · 0 citations
Open access Oct 2026

Causes of Emergency Department Admission and Outcomes Among Hematologic Versus Solid Tumor Patients Admitted to a Palliative Care Unit

Background: Patients with hematologic malignancies frequently receive more aggressive end-of-life care and are less likely to receive timely palliative care than those with solid tumors. There is still little data, though, comparing the short-term outcomes of patients later admitted to inpatient palliative care units w...

W. A. Bokhari, Sumaia A. Felimban, S. M. Aljunaid · 0 citations
Review Open access Oct 2026

Development of clinical criteria for primary oncology service involvement among solid tumor inpatients at MD Anderson Cancer Center.

67 Background: Across the US, hospitalists increasingly manage solid tumor inpatients, yet the role of primary oncologists in this model is often undefined. At MD Anderson Cancer Center, consult rates by oncology services vary by more than two-fold across the four hospitalist-managed solid tumor departments. Pr...

K. Adelson, L. Pantoja, L. Jackson et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.